Tower Research Capital (TRC)’s Sagimet Biosciences SGMT Stock Holding History

Tower Research Capital (TRC)’s Portfolio SGMT Stock Details SGMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.57K	Buy	+1,641	New	+$9.15K	﹤0.01%	3963
2025 Q4	–	Sell	-541	Closed	-$3.71K	–	5538
2025 Q3	$3.71K	Sell	541 -4,066	-88%	-$33K	﹤0.01%	4462
2025 Q2	$35.1K	Buy	+4,607	New	+$19.4K	﹤0.01%	3274
2024 Q4	–	Sell	-5,432	Closed	-$15K	–	5966
2024 Q3	$15K	Sell	5,432 -16,412	-75%	-$50.6K	﹤0.01%	3425
2024 Q2	$74.7K	Buy	21,844 +19,111	+699%	+$87.7K	﹤0.01%	2795
2024 Q1	$14.8K	Buy	2,733 +729	+36%	+$5.24K	﹤0.01%	3283
2023 Q4	$10.9K	Sell	2,004 -522	-21%	-$2.46K	﹤0.01%	4193
2023 Q3	$22.2K	Buy	+2,526	New	+$33.6K	﹤0.01%	3278

Other funds holding SGMT

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Tower Research Capital (TRC)'s SGMT Position: Q1 2026 in Review

Tower Research Capital (TRC) opened a new position in Sagimet Biosciences (SGMT) in Q1 2026: 1,641 shares worth $8.57K. The stake represents ﹤0.01% of the portfolio and ranks #3963 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in SGMT as recently as Q3 2025.

Tower Research Capital (TRC) first reported a position in SGMT in Q3 2023 and has held it in 8 quarters since. The position peaked at $74.7K in Q2 2024. 88 funds tracked by Wall St. Rank hold SGMT as of Q1 2026.

Tower Research Capital (TRC) held 1,641 shares of Sagimet Biosciences worth $8.57K as of Q1 2026.
Sagimet Biosciences was a new Tower Research Capital (TRC) position in Q1 2026.
Sagimet Biosciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q1 2026, its #3963 holding.
Tower Research Capital (TRC) first reported a position in Sagimet Biosciences in Q3 2023 and has held it in 8 quarters since.
Tower Research Capital (TRC)'s Sagimet Biosciences position peaked at $74.7K in Q2 2024.
88 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q1 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q1 2026, filed 15 May 2026.